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Abstract
The tumor microenvironment containsmultiple cancer-supporting factors, whose joint activities promote malignancy.
Here, we show that epidermal growth factor (EGF) and estrogen upregulate in an additivemanner the transcription and
the secretion of the angiogenic chemokine CXCL8 (interleukin 8 [IL-8]) in breast tumor cells. In view of published find-
ings on cross-regulatory interactions between EGF receptors and estrogen receptors in breast tumor cells, we asked
whether the additive effects of EGF and estrogen were due to their ability to (1) induce intracellular cross talk and am-
plify shared regulatory pathways or (2) act in independentmechanisms, which complement each other.We found that
stimulation by EGF alone induced the release of CXCL8 through signaling pathways involving ErbB2, ErbB1, Erk, and
phosphoinositide 3-kinase (PI3K). ErbB2 and Erk were also involved in estrogen activities on CXCL8 but to a lower ex-
tent than with EGF. However, in the joint stimulatory setup, the addition of estrogen to EGF has led to partial (ErbB2,
ErbB1, Erk) or complete (PI3K) shutoff of the involvement of these activation pathways in CXCL8 up-regulation. Further-
more, when costimulation by EGF + estrogen was applied, the effects of estrogen were channeled to regulation of
CXCL8 at the transcription level, acting through the transcription factor estrogen receptor α (ERα). In parallel, in the
joint stimulation, EGF acted independently at the transcription level through AP-1, to upregulate CXCL8 expression.
The independent activities of EGF and estrogen on CXCL8 transcription reinforce the need to introduce simultaneous
targeting of ErbBs and ERα to achieve effective therapy in breast cancer.
Neoplasia (2011) 13, 230–243
Introduction
The microenvironment of breast tumors is enriched with a variety of
factors, acting together to promote processes of cancer development
and progression. The coordinated activities of these elements and the
interactions between themmay have major clinical implications. There-
fore, it is important to identify cross-regulatory mechanisms that take
place between different promalignancy factors in breast cancer.
In this study, we were interested in cross-regulatory interactions that
may affect the release of angiogenic factors by breast tumor cells. To
achieve this goal, we selected the chemokine CXCL8 as the angiogenic
target and epidermal growth factor (EGF) and estrogen as stimulants.
CXCL8 was the target of choice because it is a powerful angiogenic
factor that exerts a variety of additional promalignancy activities in
breast cancer and is causatively involved in tumor growth andmetastasis
(e.g., [1–10]). In endothelial cells, the signals of CXCL8 are transmit-
ted mainly through the G protein–coupled receptor CXCR2, leading
to neovascularization in many malignant diseases, including breast
cancer [1–5].
EGF and estrogen were selected as the stimulants because of in-
creasing body of evidence, indicating that there is an intracellular
Abbreviations: ERα, estrogen receptor α; PDTC, pyrrolidinedithio-carbamate ammo-
nium; PI3K, phosphoinositide 3-kinase; RTK, receptor tyrosine kinase
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cross talk between their receptors [11–16]. EGF and estrogen have
multiple and well-established promalignancy roles in breast cancer,
and their receptors serve as important therapeutic targets in this dis-
ease [17–25].
EGF signals are transmitted by members of the ErbB/HER family
of receptor tyrosine kinases (RTKs), where ErbB2 (HER2/neu) and
ErbB1 (EGFR/HER1) play important roles in EGF-induced signaling.
Cell activation by EGF then leads to downstream activation of intracel-
lular signaling molecules, primarily Erk and phosphoinositide 3-kinase
(PI3K) [17–19,26–29].
The promalignancy effects of estrogen are mediated to a great extent
through the intracellular receptor ERα, acting as a transcription factor
that binds to estrogen response elements in target genes. However, ERα
was also found to induce nongenomic signal transduction pathways,
such as Erk and PI3K [11–14,30].
The cross talk between ErbBs and ERα can be mediated by genomic
and nongenomic mechanisms. It is manifested by the ability of ERα
to directly or to indirectly activate ErbBs—mainly ErbB2 but also
ErbB1—leading to stimulation of downstream kinases. In parallel,
ErbB2/ErbB1–induced activation of different intracellular kinases leads
to the stimulation of ERα and of its coregulators, thus augmenting
the genomic activities of ERα. Recent findings suggest that such inter-
actions between ErbBs and ERα stand in the basis of de novo and ac-
quired resistance to endocrine therapies in breast cancer patients
[11,12,14–16].
Obviously, the cross talk between ErbBs and ERα may affect key
cellular functions that promote malignancy. Therefore, in this study,
we wished to identify possible interactions between EGF and estrogen
in the level of regulation of angiogenic factors, specifically focusing
on CXCL8. Our initial observations indicated that EGF and estrogen
promoted in an additive manner the transcription and the release of
CXCL8 by breast tumor cells. We therefore asked if the additive effects
of EGF and estrogen on CXCL8 expression were due to (1) their ability
to induce intracellular cross talk and amplify shared pathways that pro-
mote CXCL8 release or (2) their ability to act in independent pathways
that complement each other, together giving rise to their additive activ-
ities on CXCL8 expression.
To answer these questions, we analyzed the involvement of signaling
pathways and of transcriptional activation in the joint activities of EGF
and estrogen on CXCL8 release, in comparison to the effects of EGF
alone and of estrogen alone.
The findings of our study indicate that signaling events were
potently involved in the ability of EGF to induce CXCL8 release
by the cells, whereas estrogen less potently induced some of these
activation events. When concomitant stimulation by EGF + estrogen
was applied, estrogen partly or completely downregulated the ability
of EGF to promote CXCL8 expression through intracellular signal-
ing pathways. Rather, in the EGF + estrogen stimulatory setup, the
effects of estrogen were channeled to transcription-related activities,
mediated by ERα. Specifically, after joint stimulation by EGF + es-
trogen, estrogen upregulated CXCL8 by activating the transcriptional
activity of ERα, whereas EGF induced the expression of CXCL8
through the activation of AP-1.
These results are novel because they indicate that when CXCL8
regulation is concerned, the stimulants EGF and estrogen probably
do not act through intracellular cross talk. Rather, they act in inde-
pendent transcriptional pathways that complement each other, to-
gether giving rise to additive up-regulation of CXCL8 release by breast
tumor cells.
Our findings have major clinical relevance and implications. They
provide insight into mechanisms that may be involved in disease course
and suggest that there would be a need to introduce combination
therapies directed against EGF/ErbBs and against endocrine elements
together, to inhibit the promalignancy activities of the angiogenic che-
mokine CXCL8 in breast cancer.
Materials and Methods
Determination of CXCL8 Extracellular Expression by ELISA
Human breast carcinoma MCF-7 cells were grown overnight in
growth medium [31]. Then, the cells were washed twice in phenol
red– and serum-free Dulbecco modified Eagle medium and incubated
overnight in phenol red–free medium containing 1% dialyzed fetal
calf serum (Biological Industries, Beit Ha’emek, Israel) and estrogen
(17β-estradiol, 10−8 M; Sigma, St Louis, MO). The medium was re-
moved, and the cells were incubated in a similar medium with estrogen
for additional 48 hours (estrogen was replenished every 24 hours). EGF
(10 ng/ml, unless otherwise indicated; R&D Systems, Minneapolis,
MN) was added during the last 24 hours of incubation with estrogen.
In parallel, the treatments included stimulation by estrogen alone or
EGF alone. Control cells were grown under similar conditions, with
ethanol (the solubilizer of estrogen) used as a control for estrogen. No
EGF and/or estrogen were added to control cells.
This procedure of tumor cell stimulation was selected based on pre-
liminary kinetics studies (data not shown), performed under the follow-
ing conditions:
1. Stimulation by EGF—In preliminary studies, we found that
stimulation of the cells by EGF for 24 or 48 hours induced
up-regulation of CXCL8 release. Thereafter, throughout the
study, the actual stimulations were performed for 24 hours
only to reduce the EGF-induced proliferative effects. The stimu-
lation length was not reduced to less than 24 hours because suf-
ficient time was required to enable chemokine accumulation in
the cell supernatants.
2. Stimulation by estrogen—Because the activation of ERα takes
time to evolve, we first tested the effects of estrogen for 48 and
72 hours of stimulation. Although both conditions have induced
CXCL8 up-regulation, we performed all experiments at 72 hours
of stimulation because we found that 72 hours was required for
induction of the additive effects of EGF + estrogen on CXCL8
up-regulation.
3. Joint stimulation by EGF and estrogen—The time points were
based on the same guidelines indicated above: 24 hours for EGF
and 72 hours for estrogen.
In specific parts of the study, pharmacological inhibitors were used
in conventional concentrations: AG825 (10 μM; A. G. Scientific,
San Diego, CA), AG1478 (0.5 μM; A. G. Scientific), PD98059
(50 μM; Cayman Chemical Company, Ann Arbor, MI), LY294002
(20 μM; Alexis, San Diego, CA), ICI-182,780 (1 μM; Sigma), and
pyrrolidinedithio-carbamate ammonium (PDTC, 60 μM; Sigma).
The procedures of incubation with the drugs are given in detail in
the legends to figures. Control cells were incubated with dimethyl sulf-
oxide (DMSO; Sigma), the solubilizer of the drugs (except for PDTC
that was diluted in water). The cells were exposed to the inhibitors for
time points that would allowmaximal exposure to the inhibitors and, in
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parallel, would not damage the proliferation or the morphology of the
cells (based on kinetics analyses). Of note, in all assays, the findings
obtained by the use of inhibitors were confirmed by experiments show-
ing the involvement of the relevant proteins in CXCL8 up-regulation
by the different stimulants in ELISA assays.
CXCL8 expression in the supernatants of the cells was determined
by ELISA, using standard curves with recombinant human CXCL8
(Peprotech, Rocky Hill, NJ), at the linear range of absorbance. The
following antibodies were used: coating antibodies—mouse mono-
clonal antibodies against human CXCL8 (508402; BioLegend, San
Diego, CA); and detecting antibodies—biotinylated goat anti–human
CXCL8 antibodies (BAF208; R&D Systems). After the addition of
streptavidin–horseradish peroxidase (Jackson ImmunoResearch Labo-
ratories, West Grove, PA), the substrate TMB/E solution (Chemicon,
Temecula, CA) was added. The reaction was stopped by the addition
of 0.18 M H2SO4 and was measured at 450 nm. P values were cal-
culated by Student’s t test.
Determination of CXCL8 Transcription by
Real-time Polymerase Chain Reaction
MCF-7 cells were stimulated by EGF (6 hours), estrogen (48 hours),
or EGF + estrogen (estrogen 48 hours and EGF during the last 6 hours).
Essentially similar results were obtained when EGF stimulation was
performed for 3 hours. These stimulatory conditions were based on
kinetics analyses performed as follows:
1. Stimulation by EGF—EGF signals are induced by RTK; there-
fore, it is expected that its effects on themessenger RNA (mRNA)
level would be relatively rapid. Thus, exposure to EGF was per-
formed for 3 or 6 hours, with essentially similar results.
2. Stimulation by estrogen—The conditions were selected to allow
the transcriptional activities of ERα to come into effect. Because
72 hours of stimulation by estrogen was required to induce the
additive effects of EGF + estrogen in ELISA, 48 hours of stim-
ulation was used in the real-time analysis to guarantee effects at
the mRNA levels.
3. Joint stimulation by EGF and estrogen—The time points were
based on the same guidelines indicated above: 3 or 6 hours for
EGF and 72 hours for estrogen.
Total RNAwas isolated from the cells using the EZ-RNAkit (Biologi-
cal Industries). RNA samples were used for generation of first-strand
complementary DNA synthesis using the M-MLV reverse transcriptase
(Ambion, Austin, TX). Quantification of complementary DNA targets
by real-time polymerase chain reaction (PCR) was performed on Rotor
Gene 6000 (Corbett Life Science, Concorde, NSW, Australia), using
Rotor Gene 6000 series software. Transcripts were detected using SYBR
Green I (Thermo Fisher Scientific, Abgene, England) according to the
manufacturer’s instructions. In each reaction, two pairs of specific pri-
mers were used, designed for different axons. The sequences of the pri-
mers for CXCL8 (accession no. NM_000584) were as follows: forward
5′-TTCTGCAGCTCTGTGTGAAG-3′, reverse 5′-CAGTGTGGT-
CCACTCTCAAT-3′. The sequences of the primers for the normalizing
gene rS9 (accession no. NM_001013) were as follows: forward 5′-TTA-
CATCCTGGGCCTGAAGAT-3′ and reverse 5′-GGGATGTTCAC-
CACCTGCTT-3′. PCR amplification was performed over 40 cycles
(95°C for 15 seconds, 59°C for 20 seconds, 72°C for 15 seconds).
Dissociation curves for each primer set indicated a single product, and
no-template controls were negative after 40 cycles.
Western Blot Analysis
MCF-7 cells were stimulated by EGF and/or estrogen (see “Com-
ment” below for stimulation conditions), and were then lysed in RIPA
lysis buffer. Lysis was followed by conventionalWestern blot procedures.
The following antibodies were used: phosphorylated AKT (AF887;
R&D Systems), AKT (9272; Cell Signaling Technology, Danvers,
MA), phosphorylated Erk (F1018; R&D Systems), Erk (sc-154; Santa
Cruz Biotechnology, Santa Cruz), phosphorylated ERα (sc-12915;
Santa Cruz Biotechnology), ERα (sc-543, Santa Cruz Biotechnology),
IκBα (4814; Cell Signaling Technology), p38 (M0800; Sigma),
GAPDH (MAB374; Chemicon), phosphorylated c-Jun (sc-822; Santa
Cruz Biotechnology), and c-Jun (610326; BD Transduction Laborato-
ries, San Jose, CA). ErbB2 was immunoprecipitated by mouse anti-
bodies (OP15L; Calbiochem, Gibbstown, NJ), followed by detection
of phosphorylated ErbB2 by antibodies to phospho-tyrosine (SC-
7020, Santa Cruz Biotechnology). Protein loading was determined by
antibodies to ErbB2 (SC-284, Santa Cruz Biotechnology).
After washings, the membranes were incubated with horseradish
peroxidase (HRP)–conjugated secondary antibodies, as appropriate:
sheep anti–mouse-HRP (NA931; Amersham Pharmacia Biotech,
Buckinghamshire, UK), goat anti–rabbit-HRP (111-035-003; Jackson
ImmunoResearch Laboratories), and donkey anti–goat-HRP (705-035-
003; Jackson ImmunoResearch Laboratories). The membranes
were subjected to enhanced chemiluminescence (Amersham Pharmacia
Biotech), and bands on immunoblots were quantitated by densitometry.
Comment. All experiments were preceded by preliminary kinetics
analyses, which included time points expected to allow optimal response,
based on published literature and, on our experience, in the specific cell
systems. The time points in the preliminary studies included short ex-
posure times for phosphorylation events (minutes) and were extended
to the hour time range for transcription factors as follows (data not
shown): ErbB2, 1.5 and 10 minutes; Erk and AKT, different time
points in the range of 1 to 40 minutes; ERα, 10, 20, and 30 minutes;
IκBα, 3 to 6 hours for EGFand 3 to 54 hours for estrogen; c-Jun, 1.5,
5, and 10 minutes. On the basis of these preliminary analyses, selected
time points were used in the actual sets of experiments presented in
the figures.
Dual-Luciferase Assays
The assays were performed with the following constructs: 1) Con-
structs coding for firefly luciferase under the control of CXCL8 pro-
moter, including the 5′-flanking region from −558 to +98 bp. We
have used theCXCL8 promoter expressing eitherWTAP-1 binding site
(5′-AAG TGT GAT GAC TCA GGT TTG CCC TGA-3′) or AP-1–
mutated binding site (5′-AAG TGTGATATC TCAGGT TTGCCC
TGA-3′). Both constructs were kindly provided byDrMuhl (University
Hospital Goethe–University Frankfurt), and these are described in detail
in Hellmuth et al. [32]. 2) A construct coding for renilla luciferase was
used for normalization of the results according to transfection yields
(kindly provided by Dr Zor, Tel Aviv University).
The different constructs were transiently transfected to MCF-7 cells
by ICAFectin (InCellArt, Nantes, France). Forty-eight hours after trans-
fection, the cells were stimulated by EGF for 4 or 8 hours (with essentially
similar results; on the basis of preliminary studies and because of technical
reasons related to the length of estrogen stimulation, these experiments
were not performed with estrogen alone or with estrogen + EGF) and
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processed with the reagents provided in Dual-Luciferase Assay System
Kit (Promega,Madison,WI). Luciferase activity was determined using
the same kit according to the manufacturer’s instructions.
Results
EGF and Estrogen Additively Promote CXCL8 Release
and Transcription in Breast Tumor Cells
Human breast carcinoma MCF-7 cells are the classic model system
used in studies of possible interactions between EGF and estrogen in
breast cancer. On the basis of kinetics analyses (see Materials and
Methods), the cells were stimulated by EGF (24 hours), estrogen
(72 hours), or EGF + estrogen (estrogen 72 hours; EGF during last
24 hours). The results in Figure 1A show that EGF and estrogen, each
alone, has induced a significant up-regulation in CXCL8 release by
these tumor cells. Moreover, additive effects of the two stimulants were
observed when the cells were costimulated by EGF and estrogen con-
comitantly. The extent of additivity ranged in different experiments
and reached up to two-folds, compared with stimulation by estrogen
alone or by EGF alone (e.g., Figure 1A).
After determination of the effects of EGF, estrogen, and EGF + estro-
gen on CXCL8 release by the cells, we have determined their effects
on CXCL8 mRNA levels, in conditions selected after kinetics analyses
(see Materials and Methods). This analysis has shown that the pattern
of CXCL8 transcription was similar to that of CXCL8 protein release
(Figure 1, B and A, respectively). Each of the two factors, EGF and
estrogen, induced CXCL8 transcription, and additive effects of EGF
and estrogen were observed at this level. These results indicate that
the basis for the additive increase in CXCL8 release by the tumor
cells was increased transcription of the gene, induced additively by
EGF and estrogen.
Additive Effects of EGF + Estrogen on CXCL8 Release:
Involvement of Signaling Pathways
Increased transcription of CXCL8 by EGF and estrogen may reflect
the ability of the two stimulants to induce signaling events that even-
tually lead to transcriptional activation. To determine the roles of stim-
ulatory signaling processes in CXCL8 regulation by EGF and/or
estrogen, we first analyzed the activation of membrane-proximal events.
Specifically, we focused on ErbB2 because of its major contribution to
signal amplification in response to EGF [22,28,29].
As expected from the potent activities of EGF on the tumor cells,
ErbB2 was activated in response to EGF stimulation (Figure 2A). The
activation of ErbB2 by EGF was higher than after stimulation by estro-
gen (Figure 2A).We then askedwhether ErbB2was involved in the abil-
ity of the different stimulants to elevate the release of CXCL8 by the
tumor cells. To address this question, we determined the effects of the
specific ErbB2 inhibitor AG825 (used in conventional concentrations)
on the net increase in CXCL8 amounts in the cell supernatants after
stimulation by estrogen, EGF, or both. The net increase is indicated
as Δ in the graph (Figure 2B1).
Figure 2B1 shows that ErbB2 played an important role in EGF-
induced CXCL8 release by the cells. In parallel, estrogen activities on
CXCL8 were partly mediated through ErbB2 activation, being in line
with cross talk studies showing that estrogen-induced signaling can
lead to ErbB2 activation [11–16]. However, in the joint stimulation
Figure 1. Stimulation by EGF + estrogen additively upregulates the release and transcription of CXCL8 in MCF-7 breast carcinoma cells.
(A) CXCL8 release by the tumor cells. MCF-7 cells were grown in the presence of estrogen (72 hours), EGF (last 24 hours), EGF +
estrogen (estrogen 72 hours; EGF last 24 hours), or ethanol as control (ethanol did not affect CXCL8 release compared with untreated
cells) (time points were selected based on kinetics analyses, as described in Materials and Methods). CXCL8 extracellular expression
was determined in the supernatants of the cells by ELISA and was analyzed in the linear range of absorbance. A representative experi-
ment of n > 3 is presented. *P < .05, **P < .01 for the difference between treated and untreated cells. (B) CXCL8 transcription. MCF-7
cells were grown in the presence of estrogen (48 hours), EGF (last 6 hours), EGF + estrogen (estrogen: 48 hours; EGF: last 6 hours),
or ethanol as control (time points were selected based on kinetics analyses, as described in Materials and Methods). The CXCL8 tran-
script level was determined by quantitative real-time PCR analysis. The results were standardized by rS9 levels. The figure presents the
mean (x) ± SD of normalized values of mRNA levels in three independent experiments, all showing similar results.
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by EGF + estrogen, the roles of ErbB2 in CXCL8 up-regulation were
lower compared with its roles on stimulation by EGF alone. Therefore,
the addition of estrogen to EGF has led to a partial reduction of the
involvement of this signaling pathway in CXCL8 regulation.
In parallel, we have analyzed the involvement of ErbB1 in the ac-
tivities of EGF, estrogen, and EGF + estrogen, leading to CXCL8 release
by the tumor cells. Because ErbB1 levels in MCF-7 cells are relatively
difficult to detect technically, we focused on the inhibition of its activ-
ities by AG1478, the specific ErbB1 inhibitor (used in conventional
concentrations).We found that although EGF activities were partly me-
diated throughErbB1, those of estrogen were not (Figure 2B2). Further-
more, when costimulation by EGF + estrogen was applied, ErbB1 has
shown reduced involvement inCXCL8 up-regulation comparedwith its
roles in EGF-induced effects.
Together, the above results indicate that EGF has induced the up-
regulation of CXCL8 expression through activation of ErbB2 and
ErbB1. However, the addition of estrogen to EGF has led to partial
down-regulation of the roles played by these stimulatory signaling pro-
cesses in CXCL8 promotion.
Next, we addressed the roles of downstream signaling events in
EGF-, estrogen-, and EGF + estrogen–induced CXCL8 up-regulation.
Here, we have analyzed several mediators that are known to be involved
in EGF- and/or estrogen-induced pathways. Preliminary analyses of
such mediators—including Src [12,19], cAMP [33], and GPR30 [34,
Figure 2. The additive up-regulationofCXCL8 inducedbyEGF+estrogen: Involvement of ErbB2 andErbB1. (A) ErbB2 activation.MCF-7 cells
were stimulated by EGF (10 ng/ml), estrogen (10−8M), or EGF+estrogen (EGF: 10 ng/ml; estrogen: 10−8M) or ethanol as control for 10min-
utes. Time points were selected based on kinetics analyses as described inMaterials andMethods. ErbB2 phosphorylation was determined
byWestern blot analysis. A representative experiment of n>3 (with estrogen used for 1.5 or 10minutes) is presented. (B) The involvement of
ErbB2 (B1) and ErbB1 (B2) in EGF-, estrogen-, and EGF + estrogen–induced up-regulation of CXCL8 expression. MCF-7 cells were grown as
detailed in Figure 1A. Twohours before addition of estrogen, the cellswerepretreatedwith conventional concentrationsof the ErbB2 inhibitor
AG825 (10 μM; B1), the ErbB1 inhibitor AG1478 (0.5 μM; B2), or DMSO (control = the drug’s solubilizer). Then, the growth of the cells was
continued in absence or presence of the drug (or DMSOas control) as required. CXCL8 extracellular expressionwas determined in the super-
natants of the cells by ELISA and was analyzed in the linear range of absorbance. Δ, The net amount of CXCL8 added to cell supernatant on
stimulation. These values were used for statistical evaluations of differences between the control group and the inhibitor-treated group.
A representative experiment of n > 3 is presented. *P < .05, **P < .01, ***P < .001 for the difference between cells stimulated by EGF/
estrogen/EGF + estrogen and untreated cells.
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Figure 3. The additive up-regulation of CXCL8 induced by EGF+ estrogen: Involvement of Erk. (A) Erk phosphorylation by EGF and estrogen.
MCF-7 cells were stimulated by EGF (10 ng/ml, 4-7 minutes) or estrogen (10−8 M; the results are of 20-35 minutes of stimulation; no
substantial phosphorylation was obtained at shorter or longer exposure times; time points were selected based on kinetics analyses, as
described in Materials and Methods). Erk phosphorylation was determined by Western blot analysis. A representative experiment of n =
4 is presented. (B) The involvement of Erk in EGF-, estrogen- and EGF + estrogen–induced up-regulation of CXCL8 expression. MCF-7 cells
were grown as detailed in Figure 1A. Two hours before addition of EGF, the cells were pretreated with conventional concentrations of the
Erk inhibitor PD98059 (50 μM) or DMSO (control = the drug’s solubilizer). Then, the growth of the cells was continued in the absence or
presence of the drugs (or DMSO as control). (B1) CXCL8 extracellular expression was determined by ELISA and was analyzed in the linear
range of absorbance.Δ, Thenet amountofCXCL8 added to cell supernatant onstimulation. These valueswereused for statistical evaluations
of differences between the control group and the inhibitor-treated group. A representative experiment of n=3 is presented. *P< .05, **P<
.01, and ***P < .001 for the difference between cells stimulated by EGF/estrogen/EGF + estrogen and untreated cells. P values were cal-
culated based on original values before normalization. (B2) Dominance of estrogen over EGF in combined stimulation. The figure demon-
strates a summary of the results of the experiments presented in B1 using PD98059. An average inhibition value (% ± SD) of n = 3 is
presented. (C) Estrogen downregulates EGF-induced Erk activation. MCF-7 cells were stimulated by EGF (10 ng/ml), EGF + estrogen activa-
tion (estrogen 10−8 M + EGF 10 ng/ml), or ethanol as control for 5 to 12 minutes. Time points were selected based on kinetics analyses, as
described in Materials and Methods. Erk phosphorylation levels were determined by Western blot analysis. A representative experiment of
n = 3 is presented.
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35]—did not provide substantial basis to pursue their roles in the joint
effects of EGF + estrogen on CXCL8 release by the tumor cells (data
not shown).
In addition, we have determined the roles of Erk and PI3K in the
abilities of EGF, estrogen, and EGF + estrogen to upregulate CXCL8
release by the tumor cells. To this end, we analyzed the ability of each
stimulant to induce Erk or AKT (PI3K substrate) phosphorylation; in
parallel, we determined the effects of most conventional and specific
Erk and PI3K inhibitors (PD98059 and LY294002, respectively, used
at standard concentrations) on CXCL8 release after exposure to each of
the stimulants.
Erk phosphorylation assays indicated that EGF potently activated
Erk (Figure 3A), and its ability to upregulate CXCL8 release was largely
dependent on Erk (Figure 3B1). In contrast, when the stimulation
was performed by estrogen (following preliminary kinetics analyses,
see Materials and Methods), estrogen induced only a minor activation
of Erk (in the range of x1.24-x1.6 in four experiments; Figure 3A).
Although minimal and relatively difficult to detect, this estrogen-
induced Erk activation level probably enabled a partial participation
of Erk in estrogen-induced CXCL8 up-regulation, as determined by
the use of PD98059 (Figure 3B1). Of interest, and along the lines that
were already found before, the addition of estrogen to EGF has led to
reduced involvement of Erk in CXCL8 up-regulation (Figure 3B1)
compared with the effects of EGF alone. Figure 3B2 illustrates the
relative roles of Erk in each of the stimulatory setups, indicated by
percent inhibition of CXCL8 release obtained by the Erk inhibitor
PD98059 (average and SD of three experiments). This figure clearly
shows that estrogen dictated the magnitude of Erk-mediated responses
when joint stimulation by EGF + estrogen was introduced. Whereas,
in EGF-stimulated cells Erk was involved by 73.6% in CXCL8 induc-
tion, its involvement was downregulated to 44.8% when estrogen was
added to EGF. This “dominance” of estrogen over EGF-induced sig-
naling was due to the ability of the hormone to reduce EGF-induced
activation of Erk, indicated by substantial inhibition of EGF-induced
Erk phosphorylation (Figure 3C).
We then analyzed PI3K and found that EGF induced potent activa-
tion of this enzyme, as indicated by AKT phosphorylation (Figure 4A).
Accordingly, PI3Kwas largely involved in EGF-induced CXCL8 release
(Figure 4B1). In contrast, estrogen did not induce reproducible PI3K
activation (Figure 4A; estrogen was tested in a large variety of condi-
tions), and PI3K did not take part in estrogen-induced release of
CXCL8 (Figure 4B1). When estrogen was added to the EGF stimula-
tion, the involvement of PI3Kwas diminished and actually mirrored the
lack of PI3K involvement in estrogen activities on CXCL8 (Figure 4B1).
The involvement of PI3K in CXCL8 regulation is illustrated also in
Figure 4B2, showing that, in the presence of estrogen, the ability of
EGF to induce CXCL8 up-regulation through PI3K activation was
significantly shutoff; therefore, estrogen dictated the response and
“dominated” over the activities of EGF. It is possible that this down-
regulation of PI3K activities was due to the ability of estrogen to partly
reduce AKT phosphorylation because we have obtained in some of the
experiments an inhibitory effect of estrogen on EGF-induced AKT
activation (data not shown).
To conclude this part of the study, we found that EGF activities on
CXCL8 were mediated by ErbB2 and ErbB1 and thereafter by the
downstream mediators Erk and PI3K. Whereas estrogen could partly
induce CXCL8 through some of these signaling pathways, its addition
to EGF has led to partial or complete shutoff of the involvement of
these activation events in CXCL8 regulation.
Additive Effects of EGF + Estrogen on CXCL8 Release:
Involvement of Transcription Factors
The above results indicate that signaling pathways were not the
key mediators of CXCL8 up-regulation after stimulation by estrogen,
either alone or together with EGF. Because the prime activities of es-
trogen are mediated by the transcriptional activation of its receptor
ERα [11–14,30], the thus-far obtained findings suggested that the
activities of estrogen on CXCL8 may have been channeled to the level
of transcription.
This possibility was supported by the fact that the promoter of the
CXCL8 gene contains a binding site for ERα (Figure 5A). Because
the transcriptional activation of ERα depends to a large extent on its
phosphorylation at serine 118 [11–14,30,36,37], we asked whether
estrogen induced the phosphorylation of ERα at this site in our ex-
perimental system.Our analyses indicated that indeed, estrogen induced
the phosphorylation of ERα at serine 118 (Figure 5B1). Furthermore,
by the use of the antagonist ICI-182,780 (fulvestrant) that induces ERα
degradation [38,39], we could show that ERα had a very important
role in estrogen-induced CXCL8 up-regulation (Figure 5B2). Taken
together with the low competence of estrogen in inducing CXCL8
release through signaling pathways, the results obtained herein—on
the importance of ERα in estrogen-induced CXCL8 up-regulation
and on the phosphorylation of ERα on serine 118—indicate that estro-
gen activities through ERα were indeed channeled to the control of
CXCL8 at the transcription level.
Published findings indicate that the cross talk between EGF stimu-
lation and ERα activation is manifested by the ability of EGF to induce
the phosphorylation of ERα on serine 118 [36,37,40–42]. Accordingly,
we observed that EGF induced the activation of ERα indicated by
ERα phosphorylation on this serine residue (Figure 5B1). However,
this EGF-induced activation of ERα was not “productive” in terms
of CXCL8 up-regulation because the ability of EGF to promote
CXCL8 release was not affected by ICI-182,780 (Figure 5B2). The “in-
competence” of EGF to act through ERα to promote CXCL8 release
was also demonstrated in EGF + estrogen costimulation: Under the
costimulatory conditions, ERα was only partly involved in CXCL8
up-regulation. Because ERα was not at all involved in the sole activities
of EGF (Figure 5B2), we concluded that, in the concomitant stimu-
lation by EGF + estrogen, only estrogen has led to “productive” ERα
activation as a transcription factor, through which it promoted CXCL8
release. In addition, one cannot exclude the possibility that the activated
ERα could induce low and indirect activation of the signaling pathways
that were found to be involved in CXCL8 up-regulation, specifically of
Erk (Figure 3).
Because of these results, showing that EGF did not upregulate
CXCL8 expression by activating ERα, we determined the involve-
ment of other transcription factors in EGF activity on CXCL8. Here,
we focused on NF-κB and AP-1 because they are largely involved
in EGF activities, and they are the most substantial factors regulat-
ing the transcription of inflammatory chemokines, including of
CXCL8 in breast cancer [43–46]. Accordingly, the CXCL8 promoter
expresses the corresponding binding sites for NF-κB and AP-1
(Figure 5A).
The translocation of NF-κB to the nucleus is enabled by the degra-
dation of its inhibitor, IκBα [47]. Therefore, the level of intracellular
expression of IκBα is used as a conventional estimate of NF-κB activa-
tion, and similarly, we have used this approach in a kinetics-based analy-
sis (see Materials and Methods). The results in Figure 6A show that
IκBα levels were not at all affected by exposure to EGF, and that they
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were not changed by estrogen or EGF + estrogen stimulations, suggest-
ing that NF-κB is not involved in CXCL8 up-regulation by these stimu-
lants. Supporting these results were experiments in which the activities
of NF-κB were inhibited by the specific inhibitor PDTC (Figure 6B).
The inhibitor was used at conventional concentrations for MCF-7 cells
(60μM; andwas tested preliminary in higher concentrationwith similar
results). The results in Figure 6B show that PDTC did not affect the
release of CXCL8 in response to EGF, estrogen, or EGF + estrogen.
Here, we wish to note that we have ensured that the inhibitor was active
by using it in a parallel set of experiments of an unrelated study, where
the inhibitor was indeed functional (data not shown). On the basis of
these results, suggesting that NF-κB is not involved in EGF- and/or
estrogen-induced CXCL8 up-regulation, we did not follow this direc-
tion any further.
As indicated above, the promoter of CXCL8 expresses a binding
site for the transcription factor AP-1, composed of dimers of c-Jun
with other Jun proteins/AP-1 members [47,48]. Joined by the fact that
AP-1 is a potent inducer of CXCL8 transcription in conditions that
are related to immune activities, we raised the possibility that AP-1 is
involved in CXCL8 up-regulation in response to EGF, estrogen, or
Figure 4. The additive up-regulation of CXCL8 induced by EGF + estrogen: Involvement of PI3K. (A) AKT phosphorylation by EGF and es-
trogen. MCF-7 cells were stimulated by EGF (10 ng/ml, 4-7 minutes) or estrogen (10−8 M; the results are of 20 to 35 minutes of stimulation;
no substantial phosphorylation was obtained at shorter or longer exposure times; time points were selected based on kinetics analyses, as
described in Materials and Methods). AKT phosphorylation was determined byWestern blot analysis. A representative experiment of n> 3
is presented. (B) The involvement of PI3K in EGF-, estrogen-, and EGF + estrogen–induced up-regulation of CXCL8 expression. MCF-7 cells
were grown as detailed in Figure 1A. Two hours before addition of EGF, the cells were pretreated with conventional concentrations of the
specific PI3K inhibitor LY294002 (20 μM) or DMSO (control = the drug’s solubilizer). Then, the growth of the cells was continued in the
absence or presence of the drugs (or DMSO as control). (B1) CXCL8 extracellular expression was determined in the supernatants of the cells
by ELISA, and was analyzed in the linear range of absorbance. Δ, The net amount of CXCL8 added to cell supernatant on stimulation. These
values were used for statistical evaluations of differences between the control group and the inhibitor-treated group. A representative ex-
periment of n > 3 is presented. *P < .05, **P < .01 for the difference between cells stimulated by EGF/estrogen/EGF + estrogen and
untreated cells. (B2) Dominance of estrogen over EGF in combined stimulation. The figure demonstrates a summary of the results of
the experiments presented in B1, using LY294002. An average inhibition value (% ± SD) of n > 3 is presented.
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EGF + estrogen stimulation in the tumor cells. This possibility was
supported by chromatin immunoprecipitation studies that we have
performed with antibodies to c-Jun compared with isotype control
antibodies. These preliminary studies have provided initial solid evi-
dence to specific binding of c-Jun to the endogenous CXCL8 promoter
in MCF-7 cells and also in human breast cancer MDA-MB-231 cells
(data not shown; these studies are intended to serve as basis for future
analyses of regulation of CXCL8 transcription, which are beyond the
scope of this study).
On the basis of the above, we asked whether the different stimulatory
setups—EGF, estrogen, or EGF + estrogen—activate c-Jun. The results
in Figure 7A indicate that EGF induced potent activation of c-Jun;
however, estrogen did not. The phosphorylation of c-Jun in response
to costimulation by EGF + estrogen was similar to that with EGF alone
(Figure 7A), indicating that, in the joint stimulatory setup, it was actu-
ally EGF that induced AP-1 activation.
Additional experiments have shown that the activation of c-Jun was
completely shutoff by inhibition of ErbBs when the cells were stimu-
lated by EGFalone (Figure 7B). This finding is in line with our previous
findings, showing that ErbBs—and mainly ErbB2—are required for
EGF-induced CXCL8 expression, suggesting that the events flow from
EGF stimulation, through ErbB activation to c-Jun activation, and then
to CXCL8 up-regulation.
In parallel, additional results in Figure 7B indicate that, also in the
joint stimulatory setup, EGF was active through ErbB stimulation
that leads to c-Jun activation. These results suggest that, in the joint
Figure 5. The additive up-regulation of CXCL8 induced by EGF + estrogen: Involvement of ERα. (A) A region of the CXCL8 promoter. The
consensus sequences of ERα, NF-κB, and AP-1 are indicated in boxes, and their corresponding sequences in the CXCL8 promoter are under-
lined. Small letters: n = A/T/C/G, w = A/T, r = A/G, m = A/C, y = T/C, s = G/C, k = G/T. (B) The activation of ERα and its roles in CXCL8
regulation. (B1) Phosphorylation of ERα on serine 118. MCF-7 cells were stimulated by estrogen (10−8 M), EGF (10 ng/ml), EGF + estrogen
(estrogen 10−8M+EGF 10 ng/ml), or ethanol as control for 10minutes. Time points were selected based on kinetics analyses, as described
inMaterials andMethods. ERα phosphorylationwas determined byWestern blot analysis. A representative experiment of n=3 is presented.
(B2) ERα partlymediates the additive effects of EGF+ estrogen on CXCL8 expression.MCF-7 cells were grown as detailed in Figure 1A. Two
hours before addition of estrogen, the cells were pretreated with conventional concentrations of ICI-182,780 (1 μM) or DMSO (control = the
drug’s solubilizer). Then, the growth of the cells was continued in the absence or presence of the drug (or DMSO as control). CXCL8 extra-
cellular expression was determined in the supernatants of the cells by ELISA and was analyzed in the linear range of absorbance. Δ, The net
amount of CXCL8 added to cell supernatant on stimulation. These values were used for statistical evaluations of differences between the
control group and the inhibitor-treated group. A representative experiment of n > 3 is presented. *P < .05, **P < .01 for the difference
between cells stimulated by EGF/estrogen/EGF + estrogen and untreated cells.
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stimulation, EGF acts through ErbBs and than c-Jun, to upregulate
CXCL8 expression, whereas estrogen acts through ERα (as indicated
by Figure 5). Taken together, these findings explain why ErbB2
was only partly involved in EGF + estrogen–induced CXCL8 up-
regulation (as shown in Figure 2), and support the involvement of
c-Jun in the ability of EGF to induce CXCL8 up-regulation.
The above results indicated that it was actually EGF that has induced
c-Jun activation in the tumor cells. On the basis of these results, we
wished to determine the possibility that EGF promoted through
AP-1 the transcription of CXCL8, leading to increased synthesis
of the chemokine and to its elevated release by the tumor cells. To
see if this was indeed the case, we looked for appropriate manners
to determine the roles of AP-1 in regulating EGF-induced CXCL8
expression. In the absence of a specific inhibitor of c-Jun, we took
the small hairpin RNA approach and also used the dominant nega-
tive variant of c-Jun, TAM67. In agreement with the fact that c-Jun
is essential for cell proliferation [48,49], we could not obtain transient
or stable transfectants in which the expression/activation of c-Jun
was downregulated.
Therefore, we took an alternate approach and used constructs ex-
pressing the luciferase reporter, under the regulation of CXCL8 pro-
moter, where the promoter expressed the AP-1 binding site in a WT
or a mutated form. The use of the luciferase reporter enabled us to de-
termine to which extent the activation of AP-1 was required for basal
and EGF-induced CXCL8 transcription in our system of MCF-7 cells.
When the constructs of CXCL8 promoters were expressed in the
tumor cells, the basal transcription of the CXCL8 gene was extremely
reduced in the context ofmutatedAP-1 binding site (Figure 8A, lane 1 vs
lane 3). These results indicate that the basal transcription of CXCL8 is
highly dependent on AP-1. Furthermore, in the context of the AP-1–
mutated CXCL8 promoter, EGF had considerably lower ability to pro-
mote transcription (Figure 8A, lane 2 vs lane 4; and Figure 8B; Condi-
tions selected based on kinetics analyses, as indicated in Materials and
Methods). These results indicate that, in breast tumor cells, the ability of
EGF to induce the transcription of CXCL8 is highly dependent onAP-1
activation (similar analyses were not performed for estrogen-induced ac-
tivation of AP-1, because the findings of Figure 7A indicated that the
hormone did not activate the AP-1 component c-Jun).
Together, the results of this part of the study indicate that in the
combined stimulation of breast tumor cells by EGF + estrogen, EGF
promoted the transcription of CXCL8 by activating AP-1, whereas
estrogen acted through ERα. Therefore, the two stimulatory factors
Figure 6. The additive up-regulation of CXCL8 induced by EGF + estrogen: Involvement of NF-κB. (A) Activation of NF-κB determined by
expression levels of IκBα. MCF-7 cells were grown in the presence of estrogen (10−8 M, 54 hours), EGF (10 ng/ml, last 6 hours), EGF +
estrogen (estrogen: 10−8 M, 54 hours; EGF: 10 ng/ml, last 6 hours), or ethanol as control. The expression levels of IκBαwere determined by
Western blot analysis. The experiment represents similar stimulations, preformed under varying exposure times of EGF, estrogen and both
together (seeMaterials andMethods). (B) Inhibition of NF-κB activities by PDTC.MCF-7 cells were grown as detailed in Figure 1A. Two hours
before addition of EGF, the cells were pretreated with conventional concentrations of the specific NF-κB inhibitor PDTC (60 μM; diluted in
water; the drug was active in other experimental designs—data not shown). Then, the growth of the cells was continued in the absence or
presence of the drug. CXCL8 extracellular expression was determined in the supernatants of the cells by ELISA and was analyzed in the
linear range of absorbance. Δ, The net amount of CXCL8 added to cell supernatant on stimulation. These values were used for statistical
evaluations of differences between the control group and the inhibitor-treated group. A representative experiment of n = 3 is presented.
*P < .05, **P < .01 for the difference between cells stimulated by EGF/estrogen/EGF + estrogen and untreated cells.
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act in independent pathways to upregulate the transcription of CXCL8,
together giving rise to the additive production and secretion of CXCL8
by the tumor cells.
Discussion
In this study, we have provided novel insights to the molecular mecha-
nisms involved in interactions between promalignancy factors in breast
cancer.Our findings indicate that EGFand estrogen can each upregulate
the release of the angiogenic chemokine CXCL8 by breast tumor cells,
and furthermore, that they can act in an additive manner to promote
CXCL8 transcription and expression.
Our findings strengthen published studies suggesting the existence
of interactions between CXCL8 and EGF, as well as between CXCL8
and estrogen. Previous studies with neutralizing antibodies have shown
that EGF and CXCL8 act in a cooperative manner to promote the
metastatic potential of breast tumor cells [4]. Along these lines, it
was found that the overexpression of ErbB2 in breast tumor cells has
led to an increase in CXCL8 release by the cells and that CXCL8 was
expressed to a higher degree in ErbB2-positive than in ErbB2-negative
patients [8,50].
In parallel, the study of Bendrik and Dabrosin [51] has shown a
significantly positive correlation between the plasma levels of CXCL8
and of estrogen in normal breast tissues, and that there was an increased
secretion of CXCL8 by normal human breast tissue biopsies and breast
tumor cells on exposure to estrogen.
Other studies have addressed the expression and roles of CXCL8
in association with the expression of ERα. Here, it is important to
note that the roles of estrogen and of its receptor in breast cancer are
complex, and whereas estrogen is a growth factor to breast tumor
cells, the lack of ERα is used in the clinic as a marker of poor prog-
nosis [52–54]. Accordingly, ERα-negative breast tumor cells are
known to have an aggressive phenotype, and recent findings indi-
cate that they express higher CXCL8 levels than ERα-positive cells
[3,8,55,56]. The invasion potential of ERα-negative cells was regu-
lated by CXCL8 in vitro, and CXCL8 promoted the growth and
metastatic potential of ERα-negative breast tumor cells in vivo [5,6,55].
Overall, these studies indicate that CXCL8 stands in the focal
point of EGF and estrogen activities. Our findings indicate that there
is triple-factor net between these elements because EGF can act in
additivity together with estrogen to upregulate the release of CXCL8
by breast tumor cells.
Our study has taken this issue further and has performed a detailed
analysis of the molecular mechanisms involved in CXCL8 regulation by
the sole or joint activities of EGF and estrogen. Our investigation has
provided novel insights to the complexity of EGF and estrogen activities
Figure 7. The additive up-regulation of CXCL8 induced by EGF: Involvement of AP-1. (A) Activation of AP-1. MCF-7 cells were stimulated
by estrogen (10−8 M), EGF (10 ng/ml), EGF + estrogen (estrogen 10−8 M + EGF 10 ng/ml), or ethanol as control for 10 minutes. Time
points were selected based on kinetics analyses, as described in Materials and Methods. c-Jun phosphorylation was determined
by Western blot analysis. A representative experiment of n = 4 is presented. (B) Inhibition of AP-1 activation by ErbB1 + ErbB2 in-
hibitors. MCF-7 cells were pretreated with AG825 (10 μM) + AG1478 (0.5 μM) or DMSO (control = the drug’s solubilizer) for 2 hours.
Then, the cells were incubated for additional 10 minutes in the presence of EGF (10 ng/ml), estrogen + EGF (estrogen 10−8 M; EGF
10 ng/ml), or ethanol as control. c-Jun phosphorylation was determined by Western blot analysis. A representative experiment of n = 2
is presented.
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and of CXCL8 regulation. When EGF acted alone, it upregulated
CXCL8 by activating signaling pathways (Erk and, to some extent,
also PI3K) and the transcription of the CXCL8 gene through AP-1.
In contrast, when estrogen was the sole stimulant, its ability to promote
CXCL8 release was only partly mediated by the Erk pathway, and its
activities were channeled to the activation of ERα, acting in this context
as a transcription factor on the CXCL8 gene.
Of interest were the events taking place in joint stimulation of the
cells by EGF + estrogen. Under these conditions, the relatively low
potential of estrogen to control CXCL8 expression by the signaling
pathways dominated over the more potent effects of EGF on Erk and
PI3K activation. Specifically, the addition of estrogen to EGF has led to
partial (Erk) or complete (PI3K) reduction in the involvement of these
pathways in CXCL8 regulation. Nevertheless, it is possible that the
remaining activities of Erk in the joint stimulation reflect both direct
activation by EGF, as well as indirect stimulation due to estrogen-
induced ERα activation, that could lead through intracellular cross talk
to the stimulation of this enzyme.
These observations indicate that EGF and estrogen can act indepen-
dently to promote CXCL8 release by breast tumor cells and that their
activities are additive. Therefore, in conditions where both ErbBs and
ERα are active, there would be a need to target both pathways to
achieve an effective inhibition of CXCL8 release by the tumor cells.
On the basis of the literature, such an approach would be important
in two clinical conditions:
1. Breast cancer patients expressing both ErbBs and ERα: The
expression patterns of ERα and ErbBs differ considerably in
breast cancer patients. Whereas the expression of ERα prevails
in 70% to 80% of the patients, amplification and overexpres-
sion of ErbB2 are denoted in 20% to 25% of the patients. On
the basis of immunohistochemistry analysis, it was found that
approximately half of the ErbB2-positive patients are ERα-
positive, that is, approximately 10% of the patients overall [57].
In this specific subpopulation of patients, EGF and estrogen
could each act independently through ErbBs and ERα, respec-
tively, to promote the release of CXCL8 by the tumor cells.
2. Patients manifesting interactions between ErbBs and ERα: The
regulation of estrogen, its receptors, and their interactions with
RTKs—such as ErbBs—are complex and much is still to be
learnt. However, recent studies suggest that each of the two path-
ways can regulate the other at the level of receptor expression/
activation. Between others, it was found that anti-RTK therapies
can activate the estrogen-related pathway and vice versa. To give
only few examples, the study by Xia et al. has shown that long-
term treatment of breast cancer patients with lapatinib, the dual
inhibitor of ErbB1/ErbB2, was associated with increased signal-
ing by estrogen receptors. Also, lapatinib induced ER signaling
in tumor biopsies from patients with ErbB2-overexpressing
breast cancers [20,58]. In parallel, endocrine treatment of estro-
gen receptor–positive breast cancer has led to endocrine resis-
tance, associated with increased expression and signaling by
ErbB1/ErbB2 [20,59].
The above findings suggest that, in patients treated with inhib-
itors to only one of the two pathways, the other pathway may be
amplified. Therefore, in patients treatedwith anti-RTKdrugs, the
endocrine pathway may be activated and vice versa. Under these
conditions, the tumor cells may express elevated levels of both
ErbBs and ERα, enabling them to respond to signals provided
by EGF and estrogen. On the basis of our results, this may lead
to an additive increase in the release of CXCL8 by the tumor cells.
Our results reinforce the recently considered therapeutic approach, sug-
gesting treating specific groups of breast cancer patients with combined
Figure 8. CXCL8 transcription is regulated by the AP-1 binding site. MCF-7 cells were transfected with 1) constructs of firefly luciferase
under the control of promoters expressing WT or mutated AP-1 binding sites and 2) construct of renilla luciferase. The cells were either
not stimulated (= Control) or stimulated for 4 hours with EGF (10 ng/ml). Time points were selected based on kinetics analyses, as described
inMaterials andMethods. (A) The figure shows the x ± SD of normalized results obtained in four independent experiments, all having similar
results. In each of the experiments, the expression of luciferase firefly was normalized relatively to renilla firefly. (B) The results of part A are
presented in each of the AP-1 promoters, namely WT and mutated, as “Fold induction of luciferase units (EGF/control).” The figure presents
the x ± SD of normalized values of luciferase activation levels in four independent experiments, all showing similar results.
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therapies directed against ErbBs and ERα together [11,16,20,30].
When CXCL8 regulation is concerned, patients belonging to the
above-mentioned two clinical subgroups would benefit from such
simultaneous treatment, as it would inhibit each of the two arms re-
sponsible for elevated release of CXCL8 at the tumor site: the RTK
pathway, which is mediated by ErbB1/ErbB2, and the endocrine path-
way of ERα.
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